Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

被引:106
作者
Avet-Loiseau, Herve [1 ,2 ]
Malard, Florent [2 ]
Campion, Loic [3 ]
Magrangeas, Florence [2 ]
Sebban, Catherine [4 ]
Lioure, Bruno [5 ]
Decaux, Olivier [6 ]
Lamy, Thierry [7 ]
Legros, Laurence [8 ]
Fuzibet, Jean-Gabriel [9 ]
Michallet, Mauricette [10 ]
Corront, Bernadette [11 ]
Lenain, Pascal [12 ]
Hulin, Cyrille [13 ]
Mathiot, Claire [14 ]
Attal, Michel [15 ]
Facon, Thierry [16 ]
Harousseau, Jean-Luc [17 ]
Minvielle, Stephane [2 ]
Moreau, Philippe [18 ]
机构
[1] Univ Hosp, Hematol Lab, Inst Biol, F-44093 Nantes, France
[2] INSERM, U892, Nantes, France
[3] Ctr Rene Gauducheau, Dept Stat, F-44035 Nantes, France
[4] Ctr Leon Berard, Dept Hematol, F-69373 Lyon, France
[5] Univ Hosp, Dept Hematol, Strasbourg, France
[6] Univ Hosp, Dept Internal Med, Rennes, France
[7] Univ Hosp, Dept Hematol, Rennes, France
[8] Univ Hosp, Dept Hematol, Nice, France
[9] Univ Hosp, Dept Internal Med, Nice, France
[10] Univ Hosp, Dept Hematol, Lyon, France
[11] Univ Hosp, Dept Hematol, Annecy, France
[12] Ctr Francois Baclesse, Dept Hematol, Rouen, France
[13] Univ Hosp, Dept Hematol, Nancy, France
[14] Inst Curie, Hematol Lab, Paris, France
[15] Univ Hosp, Dept Hematol, Toulouse, France
[16] Univ Hosp, Dept Hematol, Lille, France
[17] Ctr Rene Gauducheau, Dept Hematol, F-44035 Nantes, France
[18] Univ Hosp, Dept Hematol, Nantes, France
关键词
STEM-CELL TRANSPLANTATION; C-MAF; MAINTENANCE; THALIDOMIDE; EXPRESSION; SURVIVAL; THERAPY; TRIAL; GENE;
D O I
10.1182/blood-2010-07-295105
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many trials in myeloma are stratified on cytogenetic abnormalities. Among them, the most commonly chosen are the t(4;14), the del(17p), and the t(14;16). If data are well established for t(4;14) and del(17p), very few data support the use of t(14;16). To address this issue, we retro-spectively analyzed 1003 patients with newly diagnosed myeloma for this abnormality. We identified 32 patients with the t(14;16). Compared with patients lacking the t(14;16), we did not observe any difference in overall survival (P = .28). Moreover, in multivariate analyses, the t(14;16) was not prognostic (P = .39). In conclusion, our data do not support the use of t(14;16)-specific probes in the diagnostic panels of multiple myeloma. (Blood. 2011; 117(6): 2009-2011)
引用
收藏
页码:2009 / 2011
页数:3
相关论文
共 50 条
  • [41] The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma
    Roh, Jin
    Jeon, Youkyoung
    Lee, A-Neum
    Lee, Sang Min
    Kim, YeonMee
    Sung, Chang Ohk
    Park, Chan-Jeoung
    Hong, Jung Yong
    Yoon, Dok Hyun
    Suh, Cheolwon
    Huh, Jooryung
    Choi, Inhak
    Park, Chan-Sik
    ONCOTARGET, 2017, 8 (35) : 58122 - 58132
  • [42] Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
    Lakhwani, Sunil
    Mateos, Maria Victoria
    Martinez-Lopez, Joaquin
    Paiva, Bruno
    Rosinol Dachs, Laura
    Martinez, Rafael
    Oriol, Albert
    Bargay, Joan
    Gonzalez-Montes, Yolanda
    Gironella, Mercedes
    Encinas, Cristina
    Martin, Jesus
    Jarque, Isidro
    Granell, Miquel
    Abella, Eugenia
    Garcia-Mateo, Aranzazu
    Hernandez-Rivas, Jose angel
    Ramila, Elena
    Krsnik, Isabel
    Casado Montero, Luis Felipe
    De Arriba, Felipe
    Palomera, Luis
    Sampol, Antonia
    Moraleda, Jose Maria
    Casanova, Maria
    Delgado, Pilar
    Lafuente, Ana
    Amutio, Elena
    Lopez-Martinez, Aurelio
    Altes, Albert
    Ruiz, M. angeles
    Alegre, Adrian
    Lopez-Anglada, Lucia
    de la Cruz, Javier
    Alonso Fernandez, Rafael
    Blade Creixenti, Joan
    Lahuerta, Juan-Jose
    San-Miguel, Jesus
    Hernandez, Miguel-Teodoro
    ANNALS OF HEMATOLOGY, 2024, 103 (12) : 5651 - 5661
  • [43] Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma
    Ozaki, Shuji
    Harada, Takeshi
    Yagi, Hikaru
    Sekimoto, Etsuko
    Shibata, Hironobu
    Shigekiyo, Toshio
    Fujii, Shiro
    Nakamura, Shingen
    Miki, Hirokazu
    Kagawa, Kumiko
    Abe, Masahiro
    CANCERS, 2020, 12 (01)
  • [44] Multiple myeloma with t(11;14): unique biology and evolving landscape
    Bal, Susan
    Kumar, Shaji K.
    Fonseca, Rafael
    Gay, Francesca
    Hungria, Vania Tm
    Dogan, Ahmet
    Costa, Luciano J.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (07): : 2950 - 2965
  • [45] Bortezomib in combination with dexamethasone for a young multiple myeloma with t(8;14)
    Li, Jian-yong
    Wang, Li-xia
    Shen, Wen-yi
    Lu, Shi-feng
    Chen, Li-juan
    Lu, Hua
    LEUKEMIA RESEARCH, 2009, 33 (04) : 584 - 586
  • [46] Morphologic Classification Is an Important Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib or Lenalidomide
    Takakuwa, Teruhito
    Araki, Taku
    Nakamura, Koji
    Fukuyama, Tomoko
    Miura, Akiko
    Fujitani, Yotaro
    Hisanabe, Akari
    Kaieda, Anna
    Fukada, Erina
    Yamamura, Ryosuke
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2020, 50 (03) : 333 - 341
  • [47] Prognostic Value of Serum Soluble Klotho and Fibroblast Growth Factor-23 in Multiple Myeloma Patients
    Demirsoy, Esra Terzi
    Mehtap, Ozgur
    Atesoglu, Elif Birtas
    Tarkun, Pinar
    Geduk, Ayfer
    Eren, Necmi
    Hacihanefioglu, Abdullah
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (03) : 454 - 463
  • [48] Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma
    Tian, Ying
    Zhang, Yue
    Zhu, Wan-Qiu
    Chen, Xiao-Lei
    Zhou, He-Bing
    Chen, Wen-Ming
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [49] Echocardiography-defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients
    Jian, Yuan
    Zhou, Huixing
    Wang, Yidan
    Zhang, Zhiyao
    Yang, Guangzhong
    Geng, Chuanying
    Tian, Ying
    Gao, Wen
    Chen, Wenming
    CANCER MEDICINE, 2022, 11 (22): : 4182 - 4192
  • [50] CD43 is an adverse prognostic factor in newly diagnosed multiple myeloma
    Ning, Xueqin
    Wei, Xiaolei
    Chen, Bingyuan
    Li, Zhen
    Zheng, Zhongxin
    Yi, Zhengshan
    Wei, Qi
    Guo, Xutao
    Kang, Qiaoxi
    Feng, Ru
    Wei, Yongqiang
    LEUKEMIA & LYMPHOMA, 2022, 63 (11) : 2573 - 2578